EUVIMEDEUVIMED entdecken
Crossref

Oral Synbiotic Microbeads Suppress Hepatocellular Carcinoma via the Gut–Liver Axis

Zixiang Tang, Lin Deng, Yi Chen, Liwen Xiong, Yifan Qu, Wenjie Dai, Caiyi Liu, Marawan Abdelwahed, Yixing Ren, Jiebin Xie, Zhengwei Cai, Wenguo Cui und 1 weitere

Advanced Functional Materials · 20.11.2026

DOI: 10.1002/adfm.79732 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 20.11.2026. Verfasst von Zixiang Tang und 12 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben. Gefördert von: National Key Research and Development Program of China, China Postdoctoral Science Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Short‐chain fatty acids (SCFAs) suppress the initiation and progression of hepatocellular carcinoma (HCC) through the gut–liver axis. Yet their therapeutic translation is blunted by rapid hepatic first‐pass clearance, making it difficult to sustain a stable and controllable exposure. Here we develop a microfluidic route to generate hyaluronic acid methacrylate (HAMA) microspheres that encapsulate Lactobacillus rhamnosus GG (LGG), converting the distal gut into an in situ SCFA “factory” coupled to portal delivery. The 3D HAMA network buffers gastric acidity and supports distal intestinal colonization; meanwhile, gradual HAMA breakdown provides a synbiotic nutrient source that maintains microbial activity. By co‐optimizing the molecular weight of the HA precursor, microsphere diameter, and degree of methacrylation, we balance mechanical protection, mass transport, and 3D growth space to maximize distal‐gut metabolism. After sequential simulated gastric and intestinal challenges, synbiotic microspheres preserved LGG viability, producing a 5.9‐fold increase in SCFAs and reducing tumor‐cell viability by 55% in vitro. In an orthotopic HCC model, oral dosing increased intestinal bacterial burden and doubled portal‐vein SCFAs, yielding a 78% decrease in tumor volume and a ∼3‐fold rise in intratumoral CD8 + T cells. This orally administered synbiotic microsphere platform enables durable metabolic control along the gut–liver axis for HCC therapy.

Förderung

  • National Key Research and Development Program of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Tang, Z., Deng, L., Chen, Y., Xiong, L., Qu, Y., Dai, W., Liu, C., Abdelwahed, M., Ren, Y., Xie, J., Cai, Z., Cui, W., & Xiong, Y. (2026). Oral Synbiotic Microbeads Suppress Hepatocellular Carcinoma via the Gut–Liver Axis. Advanced Functional Materials. https://doi.org/10.1002/adfm.79732

Vancouver

Tang Z, Deng L, Chen Y, Xiong L, Qu Y, Dai W, et al. Oral Synbiotic Microbeads Suppress Hepatocellular Carcinoma via the Gut–Liver Axis. Advanced Functional Materials. 2026. doi:10.1002/adfm.79732

BibTeX
@article{Tang2026,
  author = {Tang, Zixiang and Deng, Lin and Chen, Yi and Xiong, Liwen and Qu, Yifan and Dai, Wenjie and Liu, Caiyi and Abdelwahed, Marawan and Ren, Yixing and Xie, Jiebin and Cai, Zhengwei and Cui, Wenguo and Xiong, Yongfu},
  title = {Oral Synbiotic Microbeads Suppress Hepatocellular Carcinoma via the Gut–Liver Axis},
  journal = {Advanced Functional Materials},
  year = {2026},
  doi = {10.1002/adfm.79732}
}
Kostenlos starten →